Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - hepatocellular


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.371
Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.

Angel Alsina · Masatoshi Kudo · Arndt Vogel · Ann-Lii Cheng · Won Young Tak · Baek-Yeol Ryoo · T. R. Jeffry Evans · Carlos López-López · Bruno Daniele · Soamnauth Misir · Min Ren · Namiki Izumi · Shukui Qin · Richard S. Finn ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.422
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).

Andrea S. Fung · Vincent C. Tam · Daniel E. Meyers · Hao-Wen Sim · Jennifer J. Knox · Valeriya O. Zaborska · Janine Marie Davies · Yoo-Joung Ko · Eugene Batuyong · Winson Y. Cheung · Haider Samawi · Richard M. Lee-Ying ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.365
Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.

Thomas Yau · Vikki Tang · Roland Ching-Yu Leung · Gin Wai Kwok · Ann-Shing Lee · Ada Law · Joanne Chiu · Bryan Li · Tan To Cheung ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.240
Insurance status and hepatocellular carcinoma: A NCDB analysis.

Hibah Ahmed · Aabra Ahmed · Katrina Wolfe · Peter T. Silberstein ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.E15638
Histone deacetylase 6-EGFR axis in recurrent hepatocellular carcinoma

Yao-Tsung Yeh · Hong-Ying Dai · Shen-Nien Wang · Pin-Jou Chang-Chien ·

Medicine
PDF

e15601Background: To investigate the role of sorafenib combined with transarterial chemoembolization (TACE) for the treatment of intermediate recurrent hepatocellular carcinoma (rHCC) after initial.

Microvascular invasion may guide selection of candidates for combination treatment with sorafenib and TACE for intermediate recurrent hepatocellular carcinoma. [10.1200/JCO.2019.37.15_SUPPL.E15601]


Objective To determine the diagnostic accuracy and predictive value of gadoxetic acid liver MRI (Gd-EOB-DTPA MRI) alone or in combination with diffusion-weighted imaging (DWI) as a second-line tool for detecting early hepatocellular carcinoma (HCC) recurrence in cirrhotic patients with previous HCC treated with resection or ablation.

Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma [10.1007/s00330-019-06351-0]


In vitro, activities against B16-F10 (mouse melanoma), HepG2 (human hepatocellular carcinoma), HL-60 (human promyelocytic leukemia) and K562 (human chronic myelocytic leukemia) and non-tumor cells: PBMC (human peripheral blood mononuclear cells activated with concanavalin A - human lymphoblast) were carried out.

Ru(II) complexes containing uracil nucleobase analogs with cytotoxicity against tumor cells. [10.1016/j.jinorgbio.2019.110751]


In vivo, they resulted in poorly differentiated hepatocellular carcinomas with a reactivation of endogenous hTERT.

In vitro transformation of primary human hepatocytes: Epigenetic changes and stemness properties. [10.1016/j.yexcr.2019.111643]


Summary Direct-acting antiviral use is associated with increased survival in hepatitis C-related hepatocellular carcinoma patients.

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma [10.1101/575670]


Highly Related Keywords from hepatocellular

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals